It fell to Bayer AG and CSL Limited to wrap up the big pharma earnings season. They faced a less desirable shared challenge – lingering impacts from past deals.
Stock Watch: Bad Deals Backfire On Bayer And CSL
Acquisition Woes Hit Stocks After Earnings Announcements
As the pharma earnings season wrapped up, it seemed like a contest to see which company's stock price dropped the most after their announcement and which made the poorest acquisition.
More from Stock Watch
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
After lowering its full-year earnings guidance just six weeks before the end of 2024, Bayer, by talking up of the prospects for its new drug launches and a major clinical trial result in 2025, might risk damaging its integrity further.
• By
CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.